Decellularized pulmonary homografts showed superior 10-year freedom from explantation versus cryopreserved homografts (96.7% vs 84.4%, P=0.029) and bovine jugular vein conduits (82.7%, P=0.012).
Cohort (n=705)
Yes
Does the use of decellularized pulmonary homografts improve freedom from explantation and structural valve degeneration compared to bovine jugular vein conduits and cryopreserved homografts in patients undergoing pulmonary valve replacement?
Decellularized pulmonary homografts for pulmonary valve replacement demonstrate excellent safety and superior freedom from explantation at 10 years compared to bovine jugular vein conduits and cryopreserved homografts.
OBJECTIVES: Decellularized pulmonary homografts (DPH) have shown excellent results for pulmonary valve replacement. However, controlled multicentre studies are lacking to date. METHODS: Prospective European multicentre trial evaluating DPH for pulmonary valve replacement. Matched comparison of DPH to bovine jugular vein (BJV) conduits and cryopreserved homografts (CH) considering patient age, type of heart defect and previous procedures. RESULTS: In total, 121 patients (59 female) were prospectively enrolled (August 2014-December 2016), age 21.3 ± 14.4 years, DPH diameter 24.4 ± 2.8 mm. No adverse events occurred with respect to surgical handling; there were 2 early deaths (30 + 59 years) due to myocardial failure after multi-valve procedures and no late mortality (1.7% mortality). After a mean follow-up of 2.2 ± 0.6 years, the primary efficacy end points mean peak gradient (16.1 ± 12.1 mmHg) and regurgitation (mean 0.25 ± 0.48, grade 0-3) were excellent. One reoperation was required for recurrent subvalvular stenosis caused by a pericardial patch and 1 balloon dilatation was performed on a previously stented LPA. 100% follow-up for DPH patients operated before or outside the trial (n = 114) included in the ESPOIR Registry, age 16.6 ± 10.4 years, diameter 24.1 ± 4.2 mm, follow-up 5.1 ± 3.0 years. The combined DPH cohort, n = 235, comprising both Trial and Registry data showed significantly better freedom from explantation (DPH 96.7 ± 2.1%, CH 84.4 ± 3.2%, P = 0.029 and BJV 82.7 ± 3.2%, P = 0.012) and less structural valve degeneration at 10 years when matched to CH, n = 235 and BJV, n = 235 (DPH 61.4 ± 6.6%, CH 39.9 ± 4.4%, n.s., BJV 47.5 ± 4.5%, P = 0.029).CONCLUSIONS: Initial results of the prospective multicentre ESPOIR Trial showed DPH to be safe and efficient. Current DPH results including Registry data were superior to BJV and CH.Trial registration clinicaltrials.gov identifier: NCT02035540.
Boethig et al. (Fri,) conducted a cohort in pulmonary valve replacement (n=705). Decellularized pulmonary homografts (DPH) vs. Bovine jugular vein (BJV) conduits and cryopreserved homografts (CH) was evaluated on mean peak gradient and regurgitation. Decellularized pulmonary homografts showed superior 10-year freedom from explantation versus cryopreserved homografts (96.7% vs 84.4%, P=0.029) and bovine jugular vein conduits (82.7%, P=0.012).